Real-World Data: Survival Outcomes and Risk Factors in Extracorporeal Membrane Oxygenation Use of Cancer Patient

ECMO may be an option in highly selected patients with solid tumors and without significant metabolic derangements. Elevated lactate and low albumin predict poor outcomes, highlighting the need for early metabolic optimization. ECMO is a potential bridge therapy for critically ill cancer patients, warranting further validation and assessment of the impact of modern oncologic therapies on outcomes. Only 3 patients in this study had hematologic malignancies. Therefore, the findings primarily reflect outcomes in patients with solid tumors and should not be generalized to those with hematologic cancers.